Back

Point of Focus Debate: Against

Against the Role of Inflammatory Markers in Renal Cell Carcinoma Prognosis: The Missing Link Between Evidence of Association and Clinical Applicability

By: Alessandro Larchera b , Paolo Dell’Oglioa b, Andrea Saloniaa b and Umberto Capitanioa b

EU Focus, Volume 2 Issue 4, October 2016, Pages 343-344

Published online: 01 October 2016

Abstract Full Text Full Text PDF (162 KB)

Take Home Message

Although an association between inflammatory markers (IMs) and renal cell carcinoma (RCC) prognosis has been proven, how to translate such information into treatment strategy has not been determined. The strongest argument against the use of IMs in the management of patients diagnosed with RCC is the missing link between evidence of association and clinical applicability.

Footnotes

a Unit of Urology, University Vita-Salute, San Raffaele Scientific Institute, Milan, Italy

b Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy

Corresponding author. Department of Urology, Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132 Milan, Italy. Tel. +39 02 26437286.

Place a comment

Your comment *

max length: 5000